Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica
暂无分享,去创建一个
S. Wacholder | M. Sherman | W. Quint | D. Solomon | A. Hildesheim | A. Rodriguez | M. Schiffman | L. van Doorn | C. Porras | P. González | R. Herrero | Sophia S. Wang | Sarah Coseo | Silvia E Jiménez | C. Bougelet | M. Safaeian | Silvia E. Jiménez
[1] L. Pinto,et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine , 2008, Human vaccines.
[2] Diane Solomon,et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. , 2008, Vaccine.
[3] O. Leo,et al. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. , 2008, Gynecologic oncology.
[4] S. Franceschi,et al. Human Papillomavirus Infection in Ulaanbaatar, Mongolia: A Population-Based Study , 2008, Cancer Epidemiology Biomarkers & Prevention.
[5] M. Stanley. Immunobiology of HPV and HPV vaccines. , 2008, Gynecologic oncology.
[6] J. Paavonen. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials , 2008, Current medical research and opinion.
[7] I. Wang,et al. Seroprevalence and risk factors for human papillomavirus in Taiwan. , 2007, Journal of tropical pediatrics.
[8] J. Dungan. Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial , 2008 .
[9] F. Sitas,et al. The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV‐16, HPV‐18, and HPV‐11 capsid‐antigens in mothers and their children , 2007, Journal of medical virology.
[10] S. Franceschi,et al. Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea , 2007, Cancer Epidemiology Biomarkers & Prevention.
[11] M. Lehtinen,et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[12] W. Quint,et al. Comparison of the SPF10-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica , 2007, Journal of Clinical Microbiology.
[13] Elizabeth R Unger,et al. Prevalence of HPV infection among females in the United States. , 2007, JAMA.
[14] X. Castellsagué,et al. Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women , 2006, Pediatrics.
[15] W. Quint,et al. Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.
[16] K. Syrjänen,et al. Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil. , 2006, European journal of obstetrics, gynecology, and reproductive biology.
[17] R. DeSalle,et al. The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.
[18] K. Straif,et al. Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.
[19] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[20] M. Sherman,et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica , 2003, British Journal of Cancer.
[21] M. Lehtinen,et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. , 2003, The Journal of general virology.
[22] W. Reeves,et al. Seroprevalence of human papillomavirus type 16 infection in the United States. , 2002, The Journal of infectious diseases.
[23] Howard D. Strickler,et al. Enhanced Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Virus-Like Particles of Human Papillomavirus , 2002, Journal of Clinical Microbiology.
[24] P. Coursaget,et al. Prevalence of Anti-Human Papillomavirus Type 16, 18, 31, and 58 Virus-Like Particles in Women in the General Population and in Prostitutes , 2001, Journal of Clinical Microbiology.
[25] S Wacholder,et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. , 2000, JAMA.
[26] J. Dillner,et al. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children , 1999, International journal of cancer.
[27] H. Hollema,et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas , 1996, Journal of clinical microbiology.
[28] R. Burk,et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.
[29] Julian Peto,et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .